Bayer Hires Counsel To Look At Trasylol Disclosure

Law360, New York (October 16, 2006, 12:00 AM EDT) -- Bayer AG has appointed independent counsel to review the company’s failure to disclose to the U.S. Food and Drug Administration a study that revealed health risks posed by its heart surgery drug, Trasylol.

The company announced Friday that it had retained Fred F. Fielding from Wiley Rein & Fielding LLP to conduct a thorough investigation, and provide recommendations as to how Bayer should proceed.

“Bayer immediately initiated a full investigation into the matter and based on our investigation so far, we believe this was a serious...
To view the full article, register now.